INTERVENTION 1:	Intervention	0
Phase I: Dose Level 1 - Docetaxel 75 mg/m^2	Intervention	1
Subjects receive gefitinib 250 mg orally daily, trastuzumab 6 mg/kg intravenously every 3 weeks (after an initial dose of 8 mg/kg with cycle 1), and docetaxel 75 mg/m^2 intravenously every 3 weeks.	Intervention	2
gefitinib	CHEBI:49668	17-26
INTERVENTION 2:	Intervention	3
Phase I: Dose Level 2 - Docetaxel 60 mg/m^2	Intervention	4
Subjects receive gefitinib 250 mg orally daily, trastuzumab 6 mg/kg intravenously every 3 weeks (after an initial dose of 8 mg/kg with cycle 1), and docetaxel 60 mg/m^2 intravenously every 3 weeks.	Intervention	5
gefitinib	CHEBI:49668	17-26
DISEASE CHARACTERISTICS:	Eligibility	0
disease	DOID:4,OGMS:0000031	0-7
Histologically confirmed adenocarcinoma of the breast	Eligibility	1
adenocarcinoma	DOID:299	25-39
breast	UBERON:0000310	47-53
Metastatic disease	Eligibility	2
disease	DOID:4,OGMS:0000031	11-18
HER-2/neu overexpression (3+ by immunohistochemistry OR 2+ by fluorescence in situ hybridization)	Eligibility	3
immunohistochemistry	BAO:0000415	32-52
Measurable or evaluable disease	Eligibility	4
disease	DOID:4,OGMS:0000031	24-31
Hormone receptor status:	Eligibility	5
hormone	CHEBI:24621	0-7
receptor	BAO:0000281	8-16
Not specified	Eligibility	6
PATIENT CHARACTERISTICS:	Eligibility	7
patient	HADO:0000008,OAE:0001817	0-7
Age	Eligibility	8
age	PATO:0000011	0-3
18 and over	Eligibility	9
Sex	Eligibility	10
Male or female	Eligibility	11
male	CHEBI:30780,PATO:0000384	0-4
male	CHEBI:30780,PATO:0000384	10-14
female	PATO:0000383	8-14
Menopausal status	Eligibility	12
Not specified	Eligibility	13
Performance status	Eligibility	14
ECOG 0-2	Eligibility	15
Life expectancy	Eligibility	16
Not specified	Eligibility	17
Hematopoietic	Eligibility	18
Absolute granulocyte count  1,500/mm^3	Eligibility	19
Platelet count  100,000/mm^3	Eligibility	20
platelet count	CMO:0000029	0-14
Hepatic	Eligibility	21
AST and ALT < 2.5 times upper limit of normal (ULN) (5.0 times ULN in the presence of liver metastases)	Eligibility	22
liver	UBERON:0002107	86-91
Bilirubin < 1.5 times ULN	Eligibility	23
No unstable or uncompensated hepatic disease	Eligibility	24
disease	DOID:4,OGMS:0000031	37-44
Renal	Eligibility	25
Creatinine < 1.6 mg/dL	Eligibility	26
creatinine	CHEBI:16737	0-10
No unstable or uncompensated renal disease	Eligibility	27
disease	DOID:4,OGMS:0000031	35-42
Cardiovascular	Eligibility	28
LVEF > 45% by echocardiogram or MUGA	Eligibility	29
No prior New York Heart Association class I-IV heart disease	Eligibility	30
heart	UBERON:0000948	18-23
heart	UBERON:0000948	47-52
heart disease	DOID:114	47-60
No prolonged PR interval or atrioventricular block on ECG	Eligibility	31
prolonged pr interval	HP:0012248	3-24
atrioventricular block	HP:0001678,DOID:0050820	28-50
No unstable or uncompensated cardiac disease	Eligibility	32
disease	DOID:4,OGMS:0000031	37-44
Pulmonary	Eligibility	33
No unstable or uncompensated respiratory disease	Eligibility	34
disease	DOID:4,OGMS:0000031	41-48
No clinically active interstitial lung disease	Eligibility	35
active	PATO:0002354	14-20
interstitial lung disease	DOID:3082	21-46
Patients who are asymptomatic and have chronic stable radiographic changes are allowed	Eligibility	36
chronic	HP:0011010	39-46
stable	HP:0031915	47-53
Immunologic	Eligibility	37
No autoimmune disorders	Eligibility	38
No conditions of immunosuppression	Eligibility	39
No severe hypersensitivity to taxane or gefitinib or any of its excipients	Eligibility	40
severe	HP:0012828	3-9
hypersensitivity	GO:0002524,DOID:1205	10-26
taxane	CHEBI:36064	30-36
gefitinib	CHEBI:49668	40-49
Other	Eligibility	41
Not pregnant or nursing	Eligibility	42
Negative pregnancy test	Eligibility	43
Fertile patients must use effective contraception	Eligibility	44
No other prior or concurrent malignancy within the past 5 years except basal cell carcinoma or carcinoma in situ of the cervix	Eligibility	45
basal cell carcinoma	HP:0002671,DOID:2513	71-91
carcinoma	HP:0030731,DOID:305	82-91
carcinoma	HP:0030731,DOID:305	95-104
No other severe or uncontrolled systemic disease	Eligibility	46
severe	HP:0012828	9-15
disease	DOID:4,OGMS:0000031	41-48
No other acute or chronic medical condition that would preclude study participation	Eligibility	47
acute	HP:0011009,PATO:0000389	9-14
chronic	HP:0011010	18-25
condition	PDRO:0000129	34-43
No other significant clinical disorder or laboratory finding that would preclude study participation	Eligibility	48
disorder	OGMS:0000045	30-38
laboratory finding	OGMS:0000018	42-60
No psychiatric illness that would preclude study compliance	Eligibility	49
PRIOR CONCURRENT THERAPY:	Eligibility	50
Biologic therapy	Eligibility	51
Prior adjuvant trastuzumab (HerceptinÂ®) allowed if > 6 months elapsed before disease recurrence	Eligibility	52
adjuvant	CHEBI:60809	6-14
disease	DOID:4,OGMS:0000031	77-84
No prior trastuzumab for metastatic breast cancer	Eligibility	53
breast cancer	DOID:1612	36-49
No prior monoclonal antibodies directed at the epidermal growth factor receptor (EGFR)	Eligibility	54
monoclonal	BAO:0000503	9-19
growth factor	BAO:0002024	57-70
receptor	BAO:0000281	71-79
Chemotherapy	Eligibility	55
Prior adjuvant chemotherapy (or as first-line therapy for metastatic breast cancer) allowed	Eligibility	56
adjuvant	CHEBI:60809	6-14
breast cancer	DOID:1612	69-82
Prior adjuvant taxane allowed if completed > 6 months before diagnosis of metastatic breast cancer	Eligibility	57
adjuvant	CHEBI:60809	6-14
taxane	CHEBI:36064	15-21
breast cancer	DOID:1612	85-98
No prior docetaxel for metastatic breast cancer	Eligibility	58
breast cancer	DOID:1612	34-47
Endocrine therapy	Eligibility	59
Prior adjuvant hormonal therapy (or as first-line therapy for metastatic breast cancer) allowed	Eligibility	60
adjuvant	CHEBI:60809	6-14
breast cancer	DOID:1612	73-86
No concurrent hormonal therapy	Eligibility	61
Concurrent steroids allowed provided dose is stable	Eligibility	62
stable	HP:0031915	45-51
Radiotherapy	Eligibility	63
radiotherapy	OAE:0000235	0-12
Not specified	Eligibility	64
Surgery	Eligibility	65
surgery	OAE:0000067	0-7
Fully recovered from prior oncologic or other major surgery	Eligibility	66
surgery	OAE:0000067	52-59
No concurrent surgery within 7 days of gefitinib administration	Eligibility	67
surgery	OAE:0000067	14-21
gefitinib	CHEBI:49668	39-48
Other	Eligibility	68
Recovered from prior anticancer therapy (alopecia allowed)	Eligibility	69
alopecia	HP:0001596,DOID:987	41-49
More than 30 days since prior non-approved drug or investigational agent	Eligibility	70
drug	CHEBI:23888	43-47
No other prior EGFR-directed therapy (i.e., tyrosine kinase inhibitors)	Eligibility	71
tyrosine	CHEBI:18186	44-52
kinase	BAO:0000294	53-59
No concurrent use of any of the following medications:	Eligibility	72
Phenytoin	Eligibility	73
phenytoin	CHEBI:8107	0-9
Carbamazepine	Eligibility	74
carbamazepine	CHEBI:3387	0-13
Barbiturates	Eligibility	75
barbiturates	CHEBI:22693	0-12
Rifampin	Eligibility	76
Hypericum perforatum (St. John's wort)	Eligibility	77
No other concurrent anticancer therapy	Eligibility	78
No concurrent cardioprotective drugs	Eligibility	79
No concurrent oral retinoids	Eligibility	80
Concurrent participation in the City of Hope indium-labeled trastuzumab imaging study allowed	Eligibility	81
Outcome Measurement:	Results	0
Number of Participants With at Least One Dose Limiting Toxicity in Phase I	Results	1
Dose Limiting Toxicity (DLT) defined as any treatment-related grade 3 or greater except for hematological toxicities which must be grade 4. Interstitial Lung Disease (ILD) related to treatment should be considered as a DLT regardless of the grade.	Results	2
interstitial lung disease	DOID:3082	140-165
Time frame: 4 weeks from start of treatment, up to 2 years	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Phase I: Dose Level 1 - Docetaxel 75 mg/m^2	Results	5
Arm/Group Description: Subjects receive gefitinib 250 mg orally daily, trastuzumab 6 mg/kg intravenously every 3 weeks (after an initial dose of 8 mg/kg with cycle 1), and docetaxel 75 mg/m^2 intravenously every 3 weeks.	Results	6
gefitinib	CHEBI:49668	40-49
Overall Number of Participants Analyzed: 2	Results	7
Measure Type: Number	Results	8
Unit of Measure: participants with DLTs  2	Results	9
Results 2:	Results	10
Arm/Group Title: Phase I: Dose Level 2 - Docetaxel 60 mg/m^2	Results	11
Arm/Group Description: Subjects receive gefitinib 250 mg orally daily, trastuzumab 6 mg/kg intravenously every 3 weeks (after an initial dose of 8 mg/kg with cycle 1), and docetaxel 60 mg/m^2 intravenously every 3 weeks.	Results	12
gefitinib	CHEBI:49668	40-49
Overall Number of Participants Analyzed: 7	Results	13
Measure Type: Number	Results	14
Unit of Measure: participants with DLTs  0	Results	15
Adverse Events 1:	Adverse Events	0
Total: 2/2 (100.00%)	Adverse Events	1
Febrile neutropenia * 2/2 (100.00%)	Adverse Events	2
neutropenia	HP:0001875,DOID:1227	8-19
Haemorrhage NOS * 0/2 (0.00%)	Adverse Events	3
Abdominal pain * 0/2 (0.00%)	Adverse Events	4
abdominal pain	HP:0002027	0-14
Diarrhea * 0/2 (0.00%)	Adverse Events	5
diarrhea	HP:0002014,DOID:13250	0-8
Melaena * 0/2 (0.00%)	Adverse Events	6
Mucositis oral * 0/2 (0.00%)	Adverse Events	7
mucositis	DOID:0080178	0-9
Nausea * 0/2 (0.00%)	Adverse Events	8
nausea	HP:0002018	0-6
Vomiting * 0/2 (0.00%)	Adverse Events	9
vomiting	HP:0002013	0-8
Catheter related infection * 0/2 (0.00%)	Adverse Events	10
Infection NOS * 0/2 (0.00%)	Adverse Events	11
Leukopenia * 1/2 (50.00%)	Adverse Events	12
leukopenia	HP:0001882,DOID:615	0-10
Adverse Events 2:	Adverse Events	13
Total: 7/29 (24.14%)	Adverse Events	14
Febrile neutropenia * 1/29 (3.45%)	Adverse Events	15
neutropenia	HP:0001875,DOID:1227	8-19
Haemorrhage NOS * 1/29 (3.45%)	Adverse Events	16
Abdominal pain * 1/29 (3.45%)	Adverse Events	17
abdominal pain	HP:0002027	0-14
Diarrhea * 2/29 (6.90%)	Adverse Events	18
diarrhea	HP:0002014,DOID:13250	0-8
Melaena * 1/29 (3.45%)	Adverse Events	19
Mucositis oral * 1/29 (3.45%)	Adverse Events	20
mucositis	DOID:0080178	0-9
Nausea * 1/29 (3.45%)	Adverse Events	21
nausea	HP:0002018	0-6
Vomiting * 1/29 (3.45%)	Adverse Events	22
vomiting	HP:0002013	0-8
Catheter related infection * 1/29 (3.45%)	Adverse Events	23
Infection NOS * 2/29 (6.90%)	Adverse Events	24
Leukopenia * 0/29 (0.00%)	Adverse Events	25
leukopenia	HP:0001882,DOID:615	0-10
